,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny-04', 'thank you']
#asco22 had so many highlights, but for me, this one was at the top. and taking the time to put destiny-04 into context. thank you both! 
Oncology and HCP editorial lead @RemHealthMedia, OBRoncology and @PatientPower. Science and medical writer, former bench scientist. Tweets are my own. She/her